RecruitingPhase 2NCT06153173
Mirdametinib in Histiocytic Disorders
Studying Juvenile xanthogranuloma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Hospital Medical Center, Cincinnati
- Principal Investigator
- Ashish Kumar, MD, PhDChildren's Hospital Medical Center, Cincinnati
- Intervention
- Mirdametinib(drug)
- Enrollment
- 40 enrolled
- Eligibility
- 2 years · All sexes
- Timeline
- 2024 – 2031
Study locations (1)
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06153173 on ClinicalTrials.gov